Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?

Neuropsychobiology

Volumn 65, Issue 3, 2012, Pages 168-172

  Dawes, Sharron E ^a   Palmer, Barton W ^a,b   Meeks, Thomas ^a   Golshan, Shahrokh ^a,c   Kasckow, John ^b,d   Mohamed, Somaia ^e,f   Zisook, Sidney ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e Education and Clinical Center   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Citalopram; Cognition; Schizophrenia; Subsyndromal depression

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; NEUROLEPTIC AGENT; PLACEBO;

ADULT; AGING; ARTICLE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGING; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COGNITION DISORDERS; COMORBIDITY; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84858963511     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000331141     Document Type: Article

References (24)

1. Palmer BW, Dawes SE, Heaton RK: What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev 2009; 19: 365-384.
2. Bench CJ, Frackowiak RS, Dolan RJ: Changes in regional cerebral blood flow on recovery from depression. Psychol Med 1995; 25: 247-261.
3. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA: Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biol Psychiatry 2000; 48: 830-843.
4. Sheline YI, Barch DM, Garcia K, Gersing K, Pieper C, Welsh-Bohmer K, Steffens DC, Doraiswamy PM: Cognitive function in late life depression: Relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry 2006; 60: 58-65.
5. Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV: Citalopram augmentation for subsyndromal symptoms of depression in middleaged and older outpatients with schizophrenia and schizoaffective disorder: A randomized controlled trial. J Clin Psychiatry 2009; 70: 562-571.
6. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
7. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
8. First MB, Spitzer RL, Gibbon M: Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition with psychotic screen (scid-i/p w/psy screen). New York, Biometrics Research, New York State Psychiatric Institute, 2002.
9. Addington D, Addington J, Maticka-Tyndale E: Assessing depression in schizophrenia: The Calgary Depression Scale. Br J Psychiatry suppl 1993; 39-44. (Pubitemid 23355888)
10. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276. (Pubitemid 18039085)
11. Oltmanns TF, Neale JM: Schizophrenic performance when distractors are present: Attentional deficit or differential task difficulty? J Abnorm Psychol 1975; 84: 205-209.
12. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK: Norms for letter and category fluency: Demographic corrections for age, education, and ethnicity. Assessment 1999; 6: 147-178.
13. Partington JE, Leiter RG: Partington's pathway test. Psychol Serv Cent J 1949; 1: 9-20.
14. Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, ed 2. Tucson, Neuropsychology Press, 1993.
15. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L: The continuous performance test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res 1988; 26: 223-238.
16. Wechsler D: Wechsler Adult Intelligence Scale -ed 3 (WAIS-III). Administration and scoring manual. San Antonio, The Psychological Corporation, 1997.
17. Baron RM, Kenny DA: The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51: 1173-1182.
18. Carroll LS, Owen MJ: Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med 2009; 1: 102.
19. Potash JB, Bienvenu OJ: Neuropsychiatric disorders: Shared genetics of bipolar disorder and schizophrenia. Nat Rev Neurol 2009; 5: 299-300.
20. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM: Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 2009; 373: 234-239.
21. Tiihonen J, Wahlbeck K, Kiviniemi V: The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res 2009; 109: 10-14.
22. Elderkin-Thompson V, Mintz J, Haroon E, Lavretsky H, Kumar A: Executive dysfunction and memory in older patients with major and minor depression. Arch Clin Neuropsychol 2006; 21: 669-676. (Pubitemid 44635111)
23. Harvey PD: Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 2009; 19: 324-335.
24. Carpenter WT, Koenig JI: The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology 2008; 33: 2061-2079. (Pubitemid 351992095)